A Lesson to Learn: CTI BioPharma Corp. (CTIC) – News Heater
Home  »  Companies   »  A Lesson to Learn: CTI BioPharma Corp. (CTIC)...

A Lesson to Learn: CTI BioPharma Corp. (CTIC)

CTI BioPharma Corp. (NASDAQ:CTIC) went down by -10.13% from its latest closing price compared to the recent 1-year high of $5.76. The company’s stock price has collected -35.92% of loss in the last five trading sessions.

Is It Worth Investing in CTI BioPharma Corp. (NASDAQ :CTIC) Right Now?

Plus, the 36-month beta value for CTIC is at 0.99. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for CTI BioPharma Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $9.53, which is $5.98 above the current price. CTIC currently public float of 72.44M and currently shorts hold a 12.97% ratio of that float. Today, the average trading volume of CTIC was 6.06M shares.

CTIC’s Market Performance

CTIC stocks went down by -35.92% for the week, with a monthly drop of -22.99% and a quarterly performance of 71.50%, while its annual performance rate touched 60.63%. The volatility ratio for the week stands at 13.34% while the volatility levels for the past 30 days are set at 10.13% for CTI BioPharma Corp.. The simple moving average for the period of the last 20 days is -27.05% for CTIC stocks with a simple moving average of 17.34% for the last 200 days.

Analysts’ Opinion of CTIC

Many brokerage firms have already submitted their reports for CTIC stocks, with BTIG Research repeating the rating for CTIC by listing it as a “Buy.” The predicted price for CTIC in the upcoming period, according to BTIG Research is $7 based on the research report published on August 09th of the previous year 2021.

Stifel, on the other hand, stated in their research note that they expect to see CTIC reach a price target of $5.50. The rating they have provided for CTIC stocks is “Buy” according to the report published on May 06th, 2021.

JMP Securities gave a rating of “Mkt Outperform” to CTIC, setting the target price at $3 in the report published on June 24th of the previous year.

CTIC Trading at -22.95% from the 50-Day Moving Average

After a stumble in the market that brought CTIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.37% of loss for the given period.

Volatility was left at 10.13%, however, over the last 30 days, the volatility rate increased by 13.34%, as shares sank -16.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.52% upper at present.

During the last 5 trading sessions, CTIC fell by -35.92%, which changed the moving average for the period of 200-days by +47.92% in comparison to the 20-day moving average, which settled at $4.83. In addition, CTI BioPharma Corp. saw 43.15% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CTIC starting from Craig Adam R, who purchase 3,500 shares at the price of $1.52 back on Dec 02. After this action, Craig Adam R now owns 13,500 shares of CTI BioPharma Corp., valued at $5,337 using the latest closing price.

Stock Fundamentals for CTIC

Equity return is now at value -298.90, with -133.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam